Cystic fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis

Journal of Pediatrics

Volumn 155, Issue 6 SUPPL., 2009, Pages

  Borowitz, Drucy ^a   Robinson, Karen A ^b   Rosenfeld, Margaret ^c   Davis, Stephanie D ^d   Sabadosa, Kathryn A ^e   Spear, Stephanie L ^f   Michel, Suzanne H ^g   Parad, Richard B ^h   White, Terry B ⁱ   Farrell, Philip M ^j   Marshall, Bruce C ⁱ   Accurso, Frank J ^k  

^a UNIVERSITY AT BUFFALO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DARTMOUTH COLLEGE   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ CYSTIC FIBROSIS FOUNDATION   (United States)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CYSTIC FIBROSIS; HUMAN; INFANT; NEWBORN; NEWBORN SCREENING; NUTRITIONAL REQUIREMENT; PRACTICE GUIDELINE; PRIMARY HEALTH CARE;

CYSTIC FIBROSIS; HUMANS; INFANT; INFANT, NEWBORN; NEONATAL SCREENING; NUTRITIONAL REQUIREMENTS; PRIMARY HEALTH CARE;

EID: 77449133012     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.09.001     Document Type: Review

References (146)

1. Robinson KA, Saldanha I, McKoy N. Management of infants with cystic fibrosis: A summary of the evidence for the Cystic Fibrosis Foundation Working Group on Care of Infants with Cystic Fibrosis. J Pediatr (Insert proper citation for the submitted methodology paper in this supplement).
2. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the US Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007;147: 871-5. (Pubitemid 351664424)
3. Giglio L, Candusso M, D'Orazio C, Mastella G, Faraguna D. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr 1997;86:1162-5. (Pubitemid 27509425)
4. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005; 147(suppl):S37-41. (Pubitemid 41400257)
5. Jedlicka-Kohler I, Gotz M, Eichler I. Parents' recollection of the initial communication of the diagnosis of cystic fibrosis. Pediatrics 1996;97: 204-9. (Pubitemid 26049650)
6. Tluczek A,Koscik RL,Modaff P, Pfeil D, Rock MJ, FarrellPM, et al. Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test. J Genet Couns 2006;15:277-91. (Pubitemid 44252996)
7. Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007;369:1187-95. (Pubitemid 46546435)
8. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-relatedmanagement of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832-9. (Pubitemid 351602057)
9. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003;142:624-30. (Pubitemid 36737164)
10. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999;135:601-10. (Pubitemid 30180451)
11. Shepherd RW, Holt TL, Greer R, Cleghorn GJ, Thomas BJ. Total body potassium in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:200-5. (Pubitemid 19210213)
12. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. Curr Opin Pulm Med 2005;11:524-7. (Pubitemid 41565003)
13. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambridge KM, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992;120:533-40.
14. Walkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert K, Herzig KH, et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr 2005;40:199-201. (Pubitemid 40269742)
15. Gaskin K, Waters D, Dorney S, Gruca M, O'Halloran M, Wilcken B. Assessment of pancreatic function in screened infants with cystic fibrosis. Pediatr Pulmonol Suppl 1991;7:69-71.
16. Bellentani S, Grisendi A, Rinaldi M, Bertolani P, Costa G, Agostini M, et al. BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared. Eur J Pediatr 1984;143:145-8. (Pubitemid 15222536)
17. Greer R, Shepherd R, Cleghorn G, Bowling FG, Holt T. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;13:52-8.
18. Durie PR, Largman C, Brodrick JW, Johnson JH, Gaskin KJ, Forstner GG, et al. Plasma immunoreactive pancreatic cationic trypsinogen in cystic fibrosis: a sensitive indicator of exocrine pancreatic dysfunction. Pediatr Res 1981;15:1351-5. (Pubitemid 11018692)
19. Gillard BK, Cox KL, Pollack PA, Geffner ME. Cystic fibrosis serum pancreatic amylase: useful discriminator of exocrine function. Am J Dis Child 1984;138:577-80. (Pubitemid 14100984)
20. Watkins JB, Schoeller DA, Klein PD, Ott DG, Newcomer AD, Hofmann AF. 13C-trioctanoin: a nonradioactive breath test to detect fat malabsorption. J Lab Clin Med 1977;90:422-30. (Pubitemid 8183276)
21. Colombo C, Maiavacca R, Ronchi M, Consalvo E, Amoretti M, Giunta A. The steatocrit: a simple method for monitoring fat malabsorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987;6:926-30. (Pubitemid 18046923)
22. Remtulla MA, Durie PR, Goldberg DM. Stool chymotrypsin activity measured by a spectrophotometric procedure to identify pancreatic disease in infants. Clin Biochem 1986;19:341-7. (Pubitemid 17025966)
23. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? J Pediatr 2002;141:84-90. (Pubitemid 34774956)
24. Nissler K, Katte IV, Huebner A, Henker J. Pancreatic elastase 1 in feces of preterm and term infants. J Pediatr Gastroenterol Nutr 2001;33:28-31. (Pubitemid 32706120)
25. Kori M, Maayan-Metzger A, Shamir R, Sirota L, Dinari G. Faecal elastase 1 levels in premature and full-term infants. Arch Dis Child Fetal Neonatal Ed 2003;88:F106-8. (Pubitemid 36269530)
26. Castellani C, Cuppens H, Macek MJr., Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008;7:179-96.
27. Durie PR, Newth CJ, Forstner GG, Gall DG. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzyme supplement. J Pediatr 1980;96:862-4. (Pubitemid 10068215)
28. McClean P, Harding M, Coward WA, Green MR, Weaver LT. Measurement of fat digestion in early life using a stable isotope breath test. Arch Dis Child 1993;69:366-70. (Pubitemid 23291325)
29. Caliari S, Benini L, Sembenini C, Gregori B, Carnielli V, Vantini I. Medium-chain triglyceride absorption in patients with pancreatic insufficiency. Scand J Gastroenterol 1996;31:90-4. (Pubitemid 26018610)
30. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy: consensus committee. J Pediatr 1995;127:681-4.
31. Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994;343:85-6. (Pubitemid 24019350)
32. Schwarzenberg SJ, Wielinski CL, Shamieh I, Carpenter BL, Jessurun J, Weisdorf SA, et al. Cystic fibrosis-associated colitis and fibrosing colonopathy. J Pediatr 1995;127:565-70.
33. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9. (Pubitemid 27187781)
34. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules: correlation with in vitro lipase activity. JAMA 1990;263:2459-61. (Pubitemid 20169457)
35. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:246-59.
36. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002;1:51-75.
37. Taylor C, Willson NB, Littlewood J, Morton A, Watson H, Wolfe S, et al. Nutritional management of cystic fibrosis. 2002. Cystic Fibrosis Trust Web site. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C- 3500Nutritional-Management.pdf. Accessed January 20, 2009.
38. Holliday KE, Allen JR, Waters DL, Gruca MA, Thompson SM, Gaskin KJ. Growth of human milk-fed and formula-fed infants with cystic fibrosis. J Pediatr 1991;118:77-8.
39. Parker EM, O'Sullivan BP, Shea JC, Regan MM, Freedman SD. Survey of breast-feeding practices and outcomes in the cystic fibrosis population. Pediatr Pulmonol 2004;37:362-7. (Pubitemid 38523950)
40. Colombo C, Costantini D, Zazzeron L, Faelli N, Russo MC, Ghisleni D, et al. Benefits of breastfeeding in cystic fibrosis: a single-centre followup survey. Acta Paediatr 2007;96:1228-32. (Pubitemid 47106534)
41. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz M, Abman SH, et al. Fat-soluble-vitamin status during the first year of life in infants with cystic fibrosis identified by screening of newborns. Am J Clin Nutr 1989;50:1064-71. (Pubitemid 19280033)
42. Ellis L, Kalnins D, Corey M, Brennan J, Pencharz P, Durie P. Do infants with cystic fibrosis need a protein hydrolysate formula? A prospective, randomized comparitive trial. J Pediatr 1998;132:270-6. (Pubitemid 28125179)
43. Farrell PM, Mischler EH, Sondel SA, Palta M. Predigested formula for infants with cystic fibrosis. J Am Diet Assoc 1987;87:1353-6. (Pubitemid 18021895)
44. Canciani M, Mastella G. Absorption of a new semielemental diet in infants with cystic fibrosis. J Pediatr Gastroenterol Nutr 1985;4:735-40. (Pubitemid 15048885)
45. Kleinman R, editor. Pediatric Nutrition Handbook. 5th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2004.
46. Piazza-Waggoner C, Driscoll KA, Gilman DK, Powers SW. A comparison using parent report and direct observation of mealtime behaviors in young children with cystic fibrosis: implications for practical and empirically based behavioral assessment in routine clinical care. Child Health Care 2008;37:38-48. (Pubitemid 351451043)
47. Stark LJ, Jelalian E, Powers SW, Mulvihill MM, Opipari LC, Bowen A, et al. Parent and child mealtime behavior in families of children with cystic fibrosis. J Pediatr 2000;136:195-200. (Pubitemid 30470990)
48. Duff AJ,Wolfe SP,Dickson C, Conway SP, BrownleeKG. Feeding behavior problems in children with cystic fibrosis in the UK: prevalence and comparison with healthy controls. J Pediatr Gastroenterol Nutr 2003;36:443-7. (Pubitemid 39280880)
49. Powers SW, Patton SR, Byars KC, Mitchell MJ, Jelalian E, Mulvihill MM, et al. Caloric intake and eating behavior in infants and toddlers with cystic fibrosis. Pediatrics 2002;109:E75-5.
50. Sanders MR, Turner KM, Wall CR, Waugh LM, Tully LA. Mealtime behavior and parent-child interaction: a comparison of children with cystic fibrosis, children with feeding problems, and nonclinic controls. J Pediatr Psychol 1997;22:881-900. (Pubitemid 28086832)
51. Stark LJ, Opipari LC, Jelalian E, Powers SW, Janicke DM, Mulvihill MM, et al. Child behavior and parent management strategies at mealtimes in families with a school-age child with cystic fibrosis. Health Psychol 2005;24:274-80. (Pubitemid 40677198)
52. Simmons RJ, Goldberg S, Washington J, Fischer-Fay A, Maclusky I. Infant-mother attachment and nutrition in children with cystic fibrosis. J Dev Behav Pediatr 1995;16:183-6.
53. Birch LL. Development of food acceptance patterns. Dev Psychol 1990; 26:515-9.
54. Carruth BR, Ziegler PJ, Gordon A, Barr SI. Prevalence of picky eaters among infants and toddlers and their caregivers' decisions about offering a new food. J Am Diet Assoc 2004;104(1 Suppl. 1):s57-64. (Pubitemid 40013719)
55. Stark LJ, Jelalian E, Mulvihill MM, Powers SW, Bowen AM, Spieth LE, et al. Eating in preschool children with cystic fibrosis and healthy peers: behavioral analysis. Pediatrics 1995;95:210-5.
56. Singer LT, Nofer JA, Benson-Szekely LJ, Brooks LJ. Behavioral assessment and management of food refusal in children with cystic fibrosis. J Dev Behav Pediatr 1991;12:115-20.
57. Powers SW, Byars KC, Mitchell MJ, Patton SR, Schindler T, Zeller MH. A randomized pilot study of behavioral treatment to increase calorie intake in toddlers with cystic fibrosis. Child Health Care 2003;32:297-311. (Pubitemid 37475212)
58. Powers SW, Jones JS, Ferguson KS, Piazza-Waggoner C, Daines C, Acton JD. Randomized clinical trial of behavioral and nutrition treatment to improve energy intake and growth in toddlers and preschoolers with cystic fibrosis. Pediatrics 2005;116:1442-50. (Pubitemid 46056493)
59. Powers SW, Piazza-Waggoner C, Jones JS, Ferguson KS, Daines C, Acton JD. Examining clinical trial results with single-subject analysis: an example involving behavioral and nutrition treatment for young children with cystic fibrosis. J Pediatr Psychol 2006;31:574-81. (Pubitemid 43999582)
60. Rayner RJ, Tyrrell JC, Hiller EJ, Marenah C, Neugebauer MA, Vernon SA, et al. Night blindness and conjunctival xerosis caused by vitamin A deficiency in patients with cystic fibrosis. Arch Dis Child 1989;64:1151-6. (Pubitemid 19208719)
61. Sitrin MD, Lieberman F, Jensen WE, Noronha A, Milburn C, Addington W. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. Ann Intern Med 1987;107:51-4. (Pubitemid 17098637)
62. Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey PM, Langhough R, et al. Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. Am J Clin Nutr 1991;54:578-85. (Pubitemid 21898972)
63. Koscik RL, Farrell PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics 2004;113:1549-58. (Pubitemid 38697958)
64. Wilson DC, Rashid M, Durie PR, Tsang A, Kalnins D, Andrew M, et al. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001;138:851-5. (Pubitemid 32545586)
65. Krebs NF, Westcott JE, Arnold TD, Kluger BM, Accurso FJ, Miller LV, et al. Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 2000;48:256-61. (Pubitemid 30598784)
66. Easley D, Krebs N, Jefferson M, Miller L, Erskine J, Accurso F, et al. Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 1998;26:136-9. (Pubitemid 28078474)
67. Arvanitakis SN, Lobeck CC. Metabolic alkalosis and salt depletion in cystic fibrosis. J Pediatr 1973;82:535-6.
68. Laughlin JJ, Brady MS, Eigen H. Changing feeding trends as a cause of electrolyte depletion in infants with cystic fibrosis. Pediatrics 1981;68: 203-7. (Pubitemid 11046459)
69. Ozcelik U, Goeman A, Niper N, Coskun T, Yilmaz E, Ozgue M. Sodium chloride deficiency in cystic fibrosis patients. Eur J Pediatr 1994;153: 829-31. (Pubitemid 24314755)
70. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC: The National Academies Press; 2004.
71. Coates A, Crofton PM, Marshall T. Prospective audit of salt supplementation in CF infants [abstract]. Pediatr Pulmonol Suppl 2005;28: 345-6.
72. Adair SM, Bowen WH, Burt BA, Kumar JV, Levy SM, Pendrys DG, et al. Recommendations for Using Fluoride to Prevent and Control Dental Caries in the United States. 2001. Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov/mmwrhtml/rr5014a1.htm. Accessed January 20, 2009.
73. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis: conclusions from the CF Antioxidant Workshop. Free Radic Biol Med 2007;42:15-31.
74. Steinkamp G, Demmelmair H, Ruhl-Bagheri I, von der Hardt H, Koletzko B. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2000;31:418-23.
75. van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 1996;63:746-52. (Pubitemid 26126595)
76. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H,Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews 2004;2004:CD003177.pub2.
77. Use of formula fortified with DHA in infants with cystic fibrosis. 2009. National Institutes of Health ClinicalTrials.gov Web site. Available at:http://clinicaltrials.gov/ct/show/NCT00530244?order=1. Accessed January 20, 2009.
78. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36:230-40. (Pubitemid 37055971)
79. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br Med J 1995;310:1571-2.
80. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008;178:1238-44.
81. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
82. Gilljam H, Stenlund C, Ericsson-Hollsing A, Strandvik B. Passive smoking in cystic fibrosis. Respir Med 1990;84:289-91. (Pubitemid 20271046)
83. Campbell PW 3rd, Parker RA, Roberts BT, Krishnamani MR, Phillips JA 3rd. Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 1992;120:261-4.
84. Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand D-B, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522-37.
85. McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):250S-9S. (Pubitemid 43265229)
86. Hardy KA, Wolfson MR, Schidlow DV, Shaffer TH. Mechanics and energetics of breathing in newly diagnosed infants with cystic fibrosis: effect of combined bronchodilator and chest physical therapy. Pediatr Pulmonol 1989;6:103-8.
87. Maayan C, Bar-Yishay E, Yaacobi T, Marcus Y, Katznelson D, Yahav Y, et al. Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration 1989;55:144-51. (Pubitemid 19203971)
88. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr., Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69. (Pubitemid 350127838)
89. Phillips GE, Pike SE, Rosenthal M, Bush A. Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux. Eur Respir J 1998;12:954-7. (Pubitemid 28491673)
90. Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinsky A. Postural drainage and gastro-oesophageal reflux in infants with cystic fibrosis. Arch Dis Child 1997;76:148-50. (Pubitemid 27086886)
91. Button BM, Heine RG, Catto-Smith AG, Olinsky A, Phelan PD, Ditchfield MR, et al. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. Pediatr Pulmonol 2003;35:208-13. (Pubitemid 36246158)
92. Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinsky A. Chest physiotherapy, gastro-oesophageal reflux, and arousal in infants with cystic fibrosis. Arch Dis Child 2004;89:435-9.
93. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704. (Pubitemid 32417671)
94. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998;26:81-8. (Pubitemid 28381468)
95. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(5 Suppl):S6-52. (Pubitemid 36617275)
96. Healthcare Infection Control Practices Advisory Committee. Guideline for environmental infection control in health-care facilities. 2003. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/ ncidod/dhqp/pdf/guidelines/Enviro-guide-03.pdf. Accessed January 20, 2009.
97. American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules- United States, 2009. Pediatrics 2009;123:189-90.
98. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113: 826-30.
99. American Academy of Pediatrics Committee on Infectious Diseases. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6.
100. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008;43:169-74. (Pubitemid 351273044)
101. Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008;27:559-61.
102. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007;42:751-6. (Pubitemid 47580800)
103. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87. (Pubitemid 32938876)
104. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100. (Pubitemid 34809519)
105. Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB, Accurso FJ. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991;119:211-7.
106. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-75. (Pubitemid 26159822)
107. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321-8. (Pubitemid 29523443)
108. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry, 2007 Annual Data Report to the Center Directors, Bethesda, Maryland, ©2008 Cystic Fibrosis Foundation; 2007.
109. Littlewood J, Bevan A, Connett G, Conway S, Dodd M, Govan J, et al. Antibiotic treatment for cystic fibrosis. 2002. Cystic Fibrosis Trust Web site. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C- 3200Antibiotic-Treatment.pdf. Accessed January 20, 2009.
110. Smyth A, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003;3: CD001912.
111. Harrison CJ, Marks MI, Welch DF, Sharma BB, Baker D, Dice J. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatr Pharmacol 1985;5:7-16. (Pubitemid 15116090)
112. Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-7. (Pubitemid 24261116)
113. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305. (Pubitemid 34289705)
114. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994;70:84-9. (Pubitemid 24088956)
115. Wright GL, Harper J. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis. Lancet 1970;1:9-14.
116. Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr 1993;122:854-60. (Pubitemid 23158420)
117. Aebi C, Bracher R, Liechti-Gallati S, Tschappeler H, Rudeberg A, Kraemer R. The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis-prognostic significance. Eur J Pediatr 1995; 154(9 Suppl. 4):S69-73.
118. Ratjen F, Munck A, Kho P. Short and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: the ELITE study. Pediatr Pulm 2008;(Suppl 31):319.
119. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.AmJ Respir Crit Care Med 2003;167:841-9. (Pubitemid 36801771)
120. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4. (Pubitemid 32913526)
121. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5. (Pubitemid 27225208)
122. Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002;33: 32-7. (Pubitemid 34031552)
123. Tepper RS, Hiatt P, Eigen H, Scott P, Grosfeld J, Cohen M. Infants with cystic fibrosis: pulmonary function at diagnosis. Pediatr Pulmonol 1988;5:15-8.
124. Villa MP, Pagani J, Lucidi V, Palamides S, Ronchetti R. Nocturnal oximetry in infants with cystic fibrosis. Arch Dis Child 2001;84:50-4. (Pubitemid 32060137)
125. Mukhopadhyay S, Kirby ML, Duncan AW, Carswell F. Early focal abnormalities on chest radiographs and respiratory prognosis in children with cystic fibrosis. Br J Radiol 1996;69:122-5. (Pubitemid 26067452)
126. Littlewood J, Balfour-Lynn I, Barnes R, Bilton D, Dinwiddie R, Doull I, et al. Standards for the clinical care of children and adults with cystic fibrosis in theUnited Kingdom. 2001. Cystic Fibrosis TrustWeb site. Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C-3000Standards- of-Care.pdf. Accessed January 20, 2009.
127. KeremE,Conway S, Elborn S,Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4:7-26. (Pubitemid 40347773)
128. Martinez TM, Llapur CJ, Williams TH, Coates C, Gunderman R, Cohen MD, et al. High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1133-8. (Pubitemid 43066649)
129. Long FR,Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-61. (Pubitemid 38869388)
130. Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175:943-50. (Pubitemid 46684705)
131. LynchDA, Brasch RC,Hardy KA,WebbWR. Pediatric pulmonary disease: assessment with high-resolution ultrafast CT. Radiology 1990;176:243-8. (Pubitemid 20208144)
132. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008;63:129-34. (Pubitemid 351236476)
133. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. (Pubitemid 350190758)
134. Turner DJ, Lanteri CJ, LeSouef PN, Sly PD. Improved detection of abnormal respiratory function using forced expiration from raised lung volume in infants with cystic fibrosis. Eur Respir J 1994;7:1995-9. (Pubitemid 24366290)
135. Ranganathan SC, Bush A, Dezateux C, Carr SB, Hoo AF, Lum S, et al. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002;166:1350-7. (Pubitemid 35292701)
136. Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2004;169:928-33. (Pubitemid 38457319)
137. Ranganathan SC, Dezateux C, Bush A, Carr SB, Castle RA, Madge S, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001;358:1964-5. (Pubitemid 34072881)
138. Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-9. (Pubitemid 351919192)
139. Lum S, Gustafsson P, Ljungberg H, Hulskamp G, Bush A, Carr SB, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007;62:341-7. (Pubitemid 46591279)
140. Kraemer R. Early detection of lung function abnormalities in infants with cystic fibrosis. J R Soc Med 1989;82(Suppl 16):21-5. (Pubitemid 19264695)
141. Beardsmore CS, Bar-Yishay E, Maayan C, Yahav Y, Katznelson D, Godfrey S. Lung function in infants with cystic fibrosis. Thorax 1988; 43:545-51.
142. Godfrey S, Mearns M, Howlett G. Serial lung function studies in cystic fibrosis in the first 5 years of life. Arch Dis Child 1978;53:83-5. (Pubitemid 8301030)
143. Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003:CD001127.
144. BergeMT,Wiel E, Tiddens HA,Merkus PJ, HopWC, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2003;2:183-8. (Pubitemid 37376495)
145. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008;43:1100-6.
146. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007;42:471-6. (Pubitemid 46700947)